PROCEPT BioRobotics (PRCT) Accumulated Expenses (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Accumulated Expenses data on file, last reported at $18.5 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 23.37% year-over-year to $18.5 million in Q1 2026; TTM through Mar 2026 was $18.5 million, a 23.37% increase from a year earlier, with the FY2025 full-year figure at $23.2 million, up 7.61% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $18.5 million, down from $23.2 million in the prior quarter.
• Over the last five years, Accumulated Expenses for PRCT reached as high as $23.2 million in Q4 2025 and fell as low as $4.6 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $14.4 million across 5 years, with a median of $14.9 million in 2024.
• Across the five-year window, Accumulated Expenses soared 110.95% in 2022 and increased 7.61% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $13.4 million in 2022, then grew by 25.57% to $16.9 million in 2023, then gained by 27.55% to $21.5 million in 2024, then gained by 7.61% to $23.2 million in 2025, then declined by 20.28% to $18.5 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $18.5 million in Q1 2026, $23.2 million in Q4 2025, and $21.8 million in Q3 2025.